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Abstract Background Expression of aromatase by
malignant breast epithelial cells and/or the surrounding
stroma implies local estrogen production that could influ-
ence the outcome of endocrine therapy for breast cancer.
Methods A validated immunohistochemical assay for aro-
matase was applied to samples from the P024 neoadjuvant
endocrine therapy trial that compared tamoxifen and
letrozole. The presence of aromatase expression by tumor or
stromal cells was correlated with tumor response, treatment
induced changes in proliferation index (Ki67), relapse-free
survival (RFS) and breast cancer-specific survival (BCSS).
Results Tumor and stromal aromatase expression were
highly correlated (P = 0.0001). Tumor cell aromatase, as a
semi-continuous score, also correlated with smaller tumor
size at presentation (P = 0.01) higher baseline ER Allred
score (P = 0.006) and lower Ki67 levels (P = 0.003).
There was no significant relationship with clinical response
or treatment-induced changes in Ki67. However, in a Cox
multivariable model that incorporated a post-treatment
tumor profile (pathological T stage, N stage, Ki67 and ER
status of the surgical specimen), the presence of tumor
aromatase expression at baseline sample remained a favor-
able independent prognostic biomarker for both RFS
(P = 0.01, HR 2.3, 95% CI 1.2–4.6 for absent expression)
and BCSS (P = 0.008, HR 3.76, 95% CI 1.4–10.0).
Conclusions Autocrine estrogen synthesis may be most
characteristic of smaller, more indolent and ER-rich breast
cancers with lower baseline growth rates. However,
response to endocrine treatment may not depend on whether
the estrogenic stimulus has a local versus systemic source.
Keywords Aromatase  Letrozole  Tamoxifen 
Neoadjuvant endocrine therapy
Introduction
After the menopause, estrogen continues to be synthesized
through peripheral conversion of androgenic precursors to
estrone and estradiol by the CYP P450 enzyme aromatase
(CYP19). Since this enzyme is widely expressed, sources
M. J. Ellis (&)  Y. Tao
Siteman Cancer Center, Washington University School of
Medicine, 660 South Euclid Ave, St. Louis, MO 63119, USA
e-mail: mellis@dom.wustl.edu
Y. Tao
e-mail: ytao@im.wustl.edu
W. R. Miller
Edinburgh Breast Unit, Edinburgh University, Edinburgh,
Scotland, UK
e-mail: w.r.miller@ed.ac.uk
D. B. Evans
Novartis Institutes for BioMedical Research, Basel, Switzerland
e-mail: dean.evans@novartis.com
H. A. Chaudri Ross
Novartis Pharma AG, Basel, Switzerland
e-mail: hilary_anne.chaudri@novartis.com
Y. Miki  T. Suzuki  H. Sasano
Department of Pathology, Tohoku University School
of Medicine, Sendai, Japan
e-mail: myasuhiro@patholo2.med.tohoku.ac.jp
T. Suzuki
e-mail: stakashi@patholo2.med.tohoku.ac.jp
H. Sasano
e-mail: hsasano@patholo2.med.tohoku.ac.jp
123
Breast Cancer Res Treat (2009) 116:371–378
DOI 10.1007/s10549-008-0161-8
of estrogen for breast cancers can therefore be through the
circulation (endocrine), from within the breast stroma
(paracrine) or through synthesis by the tumor cell (auto-
crine) [1, 2]. Intra-tumoral estrogen production has been
directly demonstrated by measuring the conversion of
radio-labeled androgen to estrogen in breast cancer biopsy
material [1–3]. However correlations between biochemical
measurements of intra-tumoral estrogen synthesis and
clinical outcomes have not been firmly established, largely
because in vivo assays of aromatase activity are difficult to
execute in a large numbers of patients [4–6]. As alternative
approaches, aromatase immunohistochemistry (IHC) and
measurements of aromatase mRNA levels have been
explored [7, 8]. However, most investigators have not
validated their IHC assays against the ‘‘gold standard’’ of a
biochemical assay for intra-tumoral aromatase activity. Our
group has recently developed and characterized a mono-
clonal antibody against aromatase. The antibody has been
utilized in IHC studies which demonstrated positive cor-
relations between aromatase IHC scores and intra-tumoral
aromatase activity [9] and aromatase mRNA expression
measurements [10] in breast cancer specimens.
In this investigation we applied the aromatase IHC assay
to formalin-fixed paraffin-embedded biopsy samples
accrued from patients enrolled onto the P024 neoadjuvant
endocrine therapy study, a Phase III double blind ran-
domized trial that compared four months neoadjuvant
tamoxifen with an equivalent period of letrozole treatment
[11–13]. The design of this study provided a valuable
opportunity to evaluate simultaneously the relationship
between tumor aromatase expression and response to
neoadjuvant endocrine therapy as well as the long-term
outcomes for patients receiving adjuvant tamoxifen
treatment.
Methods
Study population and tumor bank
The P024 protocol compared four months neoadjuvant le-
trozole with tamoxifen in post-menopausal women with
clinical stage II and III hormone receptor positive (classified
as at least 10% nuclear staining for ER and/or PgR) breast
cancers that were ineligible for breast conservative surgery
[11]. The tumor bank characteristics, ER and Ki67 mea-
surements have been described previously [12, 13]. Tumor
grade, tumor histological subtype, pathological staging
information and long-term outcomes were collated from
case report forms. The long-term outcomes and the devel-
opment of the preoperative endocrine prognostic index
(PEPI) based on pathological stage, and the ER status and
Ki67 expression level of the surgical specimen has also been
published [14].
Aromatase immunohistochemistry
The aromatase monoclonal antibody #677 was raised
against native recombinant human aromatase protein.
Details of its characterization and utilization for IHC have
been previously reported [9]. Tissue sections were immu-
nostained by a biotin-streptavidin method using a Histofine
kit (Nichirei Co. Ltd., Tokyo, Japan). The antigen-antibody
complex was visualized with 3.30-diaminobenzidine solu-
tion (DAB) and counterstained with hematoxylin. Evalu-
ation of aromatase IHC was performed by assessing the
approximate percentage of cells staining (proportion score)
and classifying the level into four groups: 0 = \1%, 1 =
1–25%, 2 = 26–50%, and 3 = [50% immuno-positive
cells. The relative intensity of aromatase immune-positive
cells was classified as follows: 0 = no immunoreactivity,
1 = weak, 2 = moderate and 3 = intense immunoreactiv-
ity. When aromatase immunoreactivity was evaluated as a
semi-continuous variable, a total score was applied that was
composed of the proportion score ? relative immuno-
intensity score (SIP score). For contingency table analysis,
aromatase staining was classified as any staining present
versus absent staining. Immunohistochemical staining
patterns of normal ducts, stromal cells, adipose cells and
carcinoma cells were evaluated separately.
Statistics
All P values reported were two sided; P B 0.05 were
considered to be statistically significant. There was no
adjustment for multiple testing. The median and inter-
quartile range of the aromatase SIP score was calculated to
show the distribution of scores. Kendall’s rank correlation
coefficients were used to assess relationship between aro-
matase SIP values and Ki67, ER, and tumor size since
aromatase SIP values were ordinal variables and not nor-
mal distributed. Fisher’s exact and Chi squared tests were
used to define associations between aromatase expression
status and clinical and cell cycle responses. The non-
parametric Mann–Whitney test was applied to compare
differences in Ki67 changes between aromatase expression
positive and aromatase expression negative tumors. The
95% confidence interval of the geometric Ki67 mean was
calculated to show the size of effects in pair-wise com-
parisons. Relapse-free survival (RFS) was defined as the
interval between randomization and the earliest subsequent
breast cancer event (all local or systemic recurrences, there
were no new breast primaries recorded in this data set).
Breast cancer-specific survival (BCSS) was defined as the
372 Breast Cancer Res Treat (2009) 116:371–378
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interval between randomization and the date of death after
breast cancer relapse. For univariable analysis, survival
curves were estimated by the Kaplan–Meier product-limit
method, with a two-sided log-rank to assess statistically
significant differences. We subsequently applied a multi-
variate Cox proportional hazards regression model to
evaluate the independent prognostic relevance of aroma-
tase expression within the context of other independently
prognostic variables that were obtained upon analysis of
the surgical specimen obtained after completion of neo-
adjuvant endocrine therapy: i.e. pathological tumor size,
lymph node status, ER and Ki67 levels [14]. The
REMARK analysis for the multivariable analysis has also
been reported [14]. All statistical analyses were performed
using SAS 9.1.2 (SAS Institute Inc., Cary NC USA).
Results
Aromatase expression and correlation with baseline
pathological and clinical variables
Initially four cellular components were scored for aroma-
tase expression (fibroblast cells, adipose cells, benign
breast duct cells and invasive cancer cells). However
benign ducts and adipose tissue were very inconsistently
present in the slides available. Thus, only stromal cell
scores and invasive cancer cell scores could be adequately
studied in terms of correlations with clinical parameters.
Ultimately aromatase analysis was conducted on 197 cases
in which central analysis confirmed ER? status and 23
cases in which the ER status was known to be ER negative
in the central laboratory (with a cut point of Allred score of
0 or 2 as the definition of negative). Of these 197 ER?
cases, 192 (96 on letrozole, 96 on tamoxifen) had sufficient
tumor cells on specimens to qualify for the analysis pre-
sented in this report. Aromatase expression SIP score in the
stomal cell and tumor cell compartments were highly
correlated (Kendall’s Tau 0.46, P = 0.0001, Fig. 1a)
Tumor cell aromatase SIP score was positively correlated
with ER levels as a continuous score (Kendall’s Tau
P = 0.006, Fig. 1b), however there was no significant
correlation with progesterone receptor (PgR) level (data
not shown). Finally the aromatase SIP score in the cancer
compartment was inversely associated with Ki67 level
(Kendall’s Tau P = 0.003 Fig. 1c). To examine correla-
tions between aromatase expression and dichotomized
clinical variables the aromatase staining score was reduced
to simple present or absent categories. Of the variables
examined, both stroma and tumor epithelial aromatase
expression were associated with smaller clinical tumor size
at baseline and ER positive status as a dichotomous vari-
able (Allred 0–2 vs. Allred 3–8) but aromatase status
(present vs. absent) did not interact with the other factors
examined (patient age, tumor grade, lymph node status,
PgR and HER2 status) (Table 1).
Fig. 1 Correlations between the site of aromatase expression, ER and
Ki67 as semi-continuous variables. Box plots comparing the distri-
butions of aromatase SIP scores in stromal cells and cancer cells (a),
aromatase SIP scores in cancer cells and ER Allred scores (b) and
Ki67 percentage and aromatase SIP scores in cancer cells (c) at
baseline. The large boxes stretch from the 25th to 75th percentile, the
lines crossing the boxes are medians, the dots are means and the small
boxes are outliers.
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Aromatase expression and clinical or radiological
response to neoadjuvant letrozole or tamoxifen
A series of contingency tables were examined to identify
interactions between aromatase expression status and
response (Table 2). In the P024 study, response was
recorded according to clinical measurements, ultrasound
and mammography. There was no evidence of interactions
with any of the response definitions, whether the stroma or
the tumor cell aromatase status was examined as the
interacting factor or whether letrozole or tamoxifen treated
cases were considered separately. Consistent with a lack of
an influence on endocrine therapy responsiveness, there
was no interaction with treatment-induced changes in Ki67
or absolute post-treatment Ki67 levels in either tamoxifen
or letrozole-treated tumor samples (Table 3).
Aromatase expression and relapse-free survival
and breast cancer-specific survival
Although there was no association with neoadjuvant
response or Ki67 changes, the baseline interactions
between aromatase expression, higher ER levels and lower
Ki67 levels suggested the possibility that aromatase
expression could be a favorable prognostic biomarker for
patients undergoing adjuvant endocrine therapy. We
therefore examined the impact of aromatase expression on
RFS and BCSS (Fig. 2). Tumor aromatase expression was
Table 1 Patients and tumors
characteristics by location of
aromatase protein expression
status at baseline
a HER2 IHC with fluorescence
in situ hybridization
confirmation and IHC for ER
and PgR were performed as
previously described [12]
b Aromatase protein expression
considered positive if any
aromatase IHC staining was
present
c For age and clinical tumor
size the student’s t test was used
to compare the aromatase
positive and negative groups.
For binary variables the X2 test
was applied with Fisher’s exact
test if a count in any cell was
less than 5
Characteristics Aromatase protein expression [n (%)]b
Tumor epithelial aromatase Stromal aromatase
Negative Positive Negative Positive
Treatment
Tamoxifen 24 (53%) 72 (49%) 29 (54) 63 (48)
Letrozole 21 (47%) 75 (51%) 25 (46) 69 (52)
P-value 0.6102 0.4605
Age (year) 66.8 67.6 67.6 67
P-valuec 0.6214 0.6969
Clinical tumor size (cm) 5.7 4.8 5.5 4.7
P-valuec 0.0144 0.0398
Pre treatment grade
I 4 (10%) 16 (13%) 4 (8%) 16 (15%)
II/III 38 (90%) 103 (87%) 47 (92%) 90 (85%)
P-value 0.5971 0.3064
Pathological tumor size
B20 mm 11 (27%) 44 (32%) 11 (27%) 44 (32%)
[20 mm 30 (73%) 95 (68%) 30 (73%) 95 (68%)
P-value 0.5567 0.5567
Pathological node status
Negative 16 (41%) 55 (43%) 21 (47%) 50 (43%)
Positive 23 (59%) 72 (57%) 24 (53%) 65 (57%)
P-value 0.8017 0.7160
HER2 statusa
Negative 40 (91%) 140 (95%) 50 (93%) 125 (95%)
Positive 4 (9%) 7 (5%) 4 (7%) 6 (5%)
P-value 0.2806 0.4810
ER statusc
Negative 11 (20%) 12 (8%) 14 (20%) 9 (6%)
Positive 44 (80%) 148 (93%) 55 (80%) 131 (94%)
P-value 0.0098 0.0027
PgR statusc
Negative 16 (36%) 48 (33%) 20 (37%) 43 (33%)
Positive 28 (64%) 98 (67%) 34 (63%) 87 (67%)
P-value 0.6688 0.6072
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confirmed to have a modest association with a more
favorable disease course, with fewer relapse events over
time and a significant univariable log rank test P = 0.04
(Fig. 2a) and more prolonged breast cancer survival
(Fig. 2b P = 0.01). To determine the independence of
baseline aromatase expression as a prognostic marker in
our established multivariable models based on the post-
treatment surgical sample, the baseline aromatase status
was analyzed in the context of the preoperative endocrine
relapse index (PEPI) (Table 4) [14]. In the PEPI model
pathologic tumor size (T1/2 vs. T3/4), pathological nodal
status (negative vs. positive), Ki67 per natural log interval
and ER status post therapy (Allred 0–2 vs. Allred 3–8) have
been found to be independent factors for RFS and BCSS
[14]. When tumor aromatase status was entered into a
multivariable Cox model containing these four factors, the
presence of aromatase expression in the baseline specimen
behaved as an independent favorable prognostic biomarker
for both RFS (P = 0.01, HR 2.3 95% 1.2–4.6 for absent
expression) (Table 4A) and BCSS (P = 0.008, HR 3.76
95% CI 1.4–10.0 for absent expression) (Table 4B).
Discussion
The clinical significance of intra-tumoral estrogen pro-
duction has been debated ever since the phenomenon was
first documented by Miller et al., in 1974 [15] through the
detection of the conversion of radio-labeled androgen to
estradiol within breast cancers in vitro. This potential exists
in about 60–70% of breast cancers [1–3]. Subsequently
infusion studies with radioactive androgens showed that
estrogen biosynthesis occurred in situ within the breast [16,
17] and the presence of mRNA for aromatase, the key
enzyme in estrogen production, was also demonstrated in
breast cancers and adipose tissue [8]. Because aromatase is
the last step in the biosynthetic pathway for estradiol, the
enzyme has become a critical target for pharmacological
inhibitors that achieve endocrine deprivation for post-
menopausal patients requiring endocrine treatment for
ER? breast cancer. Consequently third-generation aroma-
tase inhibitors have evolved as the new standard of care for
breast cancer treatment for all stages of the disease. It was
therefore logical to address the possibility that the presence
of aromatase within breast cancers is associated with a
particular requirement for estrogen for growth and there-
fore whether aromatase expressing tumors are more likely
to respond to endocrine therapy in general, and to aroma-
tase inhibitors in particular.
The number of studies examining these relationships is
few, have utilized small numbers of tumors and come to
limited (often conflicting) conclusions [4, 18, 19]. The
Table 2 Analysis of clinical, mammogram and ultrasound response
data according to aromatase protein expression status in tamoxifen or
letrozole treated patients
Responses Aromatase protein expression [n (%)]
Tumor epithelial aromatase Stromal aromatase
Negative Positive Negative Positive
Clinical responsea
Letrozole only
No 6 (29%) 24 (32%) 11 (44%) 18(26)
Yes 15 (71%) 51 (68%) 14 (56%) 51(74)
P-value 0.7657 0.0984
Tamoxifen only
No 12 (50%) 37 (51%) 13 (45%) 34 (54%)
Yes 12 (50%) 35 (49%) 16 (55%) 29 (46%)
P-value 0.9067 0.4177
Fused
No 18 (40%) 61 (41%) 24 (44%) 52 (39%)
Yes 27 (60%) 86 (59%) 30 (56%) 80 (61%)
P-value 0.8587 0.5259
Mammo responsea
Letrozole only
No 13 (62%) 47 (63%) 17 (68%) 42 (61%)
Yes 8 (38%) 28 (37%) 8 (32%) 27 (39%)
P-value 0.9494 0.5297
Tamoxifen only
No 19 (79%) 54 (75%) 23 (79%) 48 (76%)
Yes 5 (21%) 18 (25%) 6 (21%) 15 (24%)
P-value 0.6803 0.7418
Fused
No 32 (71%) 101 (69%) 40 (74%) 90 (68%)
Yes 13 (29%) 46 (31%) 14 (26%) 42 (32%)
P-value 0.7604 0.4278
Ultrasound responsea
Letrozole only
No 12 (67%) 39 (56%) 16 (73%) 34 (52%)
Yes 6 (33%) 31 (44%) 6 (27%) 31 (48%)
P-value 0.4038 0.0959
Tamoxifen only
No 13 (68%) 44 (64%) 15 (60%) 41 (69%)
Yes 6 (32%) 25 (36%) 10 (60%) 18 (31%)
P-value 0.7085 0.4016
Fused
No 25 (68%) 83 (60%) 31 (66%) 75 (60%)
Yes 12 (32%) 56 (40%) 16 (34%) 49 (40%)
P-value 0.3845 0.5116
Response rate refers to the percentage of patients with a complete or
partial response
a Response definitions by WHO criteria have been previously
reported [11]. The X2 test was applied with Fisher’s exact test if a
count in any cell was less than 5
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major reason for this is that the low abundance of aroma-
tase in the breast requires sophisticated, time-consuming
and labor intensive methodology and relatively large
amounts of fresh tissue. This has precluded routine use in
large clinical trials. However the availability of an antibody
which can specifically detect aromatase in fixed archival
breast cancers has changed this. We can now report results
on the presence (and semi-quantitative levels) of aromatase
in tumor material obtained from a randomized trial of
neoadjuvant endocrine therapy (P024).
Before discussing the findings it is worth considering
methodological issues and potential limitations of the
study. Firstly, IHC estimation of protein provides no
information on activity and protein may be present that is
deactivated or inhibited [20]. This certainly will be the case
in patients treated with aromatase inhibitors. For this rea-
son we have excluded outcome correlations with aromatase
status in ‘‘on treatment’’ samples because we have not
validated relationships between aromatase activity and
expression in the presence of an endocrine agent. Secondly,
because aromatase is present in different compartments of
the breast (and at different levels) complete assessment
requires quantification of multiple tissue types and an
estimate of the relative amounts of each compartment. In
this study, to simplify these confounders, we have not used
assessments in adipose and benign tissue of tissue sections
which were generally low in staining score and proportion.
Aromatase scores were highest in the malignant and stro-
mal compartments of breast cancers. However, these were
highly related in breast cancers suggesting a field effect of
trophic factors regulating aromatase. We have therefore
restricted our correlations to the status of the cancer cells
which were reliably present in all the samples eligible for
analysis and therefore more consistent to score.
In terms of demographics we have combined the two
arms of the P024 trial for long term outcome analysis, not
discriminating between patients subsequently treated with
tamoxifen or letrozole since all patients received tamoxifen
as adjuvant therapy. This has formed a database which
represents the largest published series of breast cancers
assessed by aromatase IHC. The results show that tumor
aromatase was positively and significantly related to
smaller tumor size and ER level/status. These findings
would be consistent with data published by members of the
group on aromatase activity [4] but not with others using
IHC with a different antibody [7]. A significant inverse
correlation was observed with the proliferation marker,
Ki67. To the best of our knowledge there have been no
other published studies relating tumor aromatase to
proliferation.
In terms of endocrine responsiveness, no significant
association was detected between tumor aromatase and
clinical response to either letrozole or tamoxifen. While
positive correlations have been reported between the pres-
ence of in vitro and in vivo aromatase activity and response
to aromatase inhibitors, these relationships were not strong
and were observed in advanced disease, not in the neoad-
juvant setting [18, 19] Other studies on response to
tamoxifen have been negative. Thus, the response to endo-
crine therapy does not appear to be strongly modulated by
whether the source of estrogen is autocrine or endocrine.
Despite a failure to observe significant relationships
between aromatase expression and clinical or biomarker
response to treatment in the neoadjuvant phase of the
study, significant associations were found between the
presence of tumor aromatase expression and long-term
outcome following neoadjuvant treatment. Thus, tumors
with positive aromatase scores had significantly greater
Table 3 Paired Ki67 data before and after letrozole/tamoxifen therapy according to aromatase protein expression status in breast cancer cells/
stromal cells
Ki67 [Geometric mean (95% CI)]a Aromatase protein expression
Cancer cells Stromal cells
Negative Positive Negative Positive
Letrozole only
Pre 5.54 (2.54–12.08) 3.56 (2.47–5.14) 3.64 (1.70–7.82) 3.92 (2.69–5.72)
Post 0.70 (0.33–1.49) 0.49 (0.31–0.75) 0.88 (0.38–2.04) 0.44 (0.29–0.68)
P-valueb 0.0037 0.0001 0.0083 0.0001
Tamoxifen only
Pre 5.97 (3.17–11.24) 5.63 (4.18–7.58) 7.75 (4.46–13.47) 4.67 (3.39–6.44)
Post 1.72 (0.75–3.97) 1.36 (0.88–2.09) 1.61 (0.76–3.39) 1.23 (0.77–1.95)
P-valueb 0.0117 0.0001 0.0007 0.0001
a 95% CI: confidence Interval
b Wilcoxon signed rank test was used to compare paired Ki67 data within each group defined by aromatase expression status
376 Breast Cancer Res Treat (2009) 116:371–378
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RFS and BCSS. It is not possible to ascertain whether this
is directly caused by increased sensitivity to endocrine
therapy in the adjuvant setting. However, the lack of
association of response in the neoadjuvant situation would
not be compatible with this. Furthermore the positive
correlations with small clinical size and ER status levels
(favorable prognostic biomarkers) and the inverse corre-
lation with Ki67 (a poor prognosis biomarker) suggest that
aromatase positive tumors may be inherently less aggres-
sive. This is supported by data from multivariable analyses
in which tumor aromatase scores predicted for long-term
outcome independently of other factors that have been
shown to be predictive for outcome in the post neoadjuvant
endocrine therapy setting. This finding also implies that the
most accurate models for the prediction of outcomes for
patients with ER? disease may combine baseline prog-
nostic biomarker analysis, in combination with the ‘‘on-
treatment’’ predictive biomarker analysis derived from an
analysis of the tumor after several months of endocrine
treatment [14].
It is therefore suggested that routine IHC measurements
of aromatase in breast cancer will not generally aid
Table 4 Univariate and multivariate analysis of pathological tumor size, node status, post-treatment Ki67, post-treatment ER and pre treatment
aromatase statusa
A
Factor definitions No. of patients
in each group
No. of events/
No. of patients
Relapse-free survival
Univariable analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Tumor sizea
(T1/2 vs. T3/4)
138/33 47/171 2.7 (1.4–5.0) 0.002 2.82 (1.36–5.85) 0.006
Node status
(Yes vs. No)
90/69 44/159 3.9 (1.8–8.4) 0.0005 3.44 (1.58–7.48) 0.002
Ki67 level, per 2.7 fold increaseb 48/174 1.4 (1.2–1.6) 0.0002 1.1 (1.02–1.09) 0.003
ER Allredc
(0.2 vs. 3–8)
16/157 48/173 2.4 (1.0–5.3) 0.04 2.74 (1.1–6.67) 0.03
Aromatase statusd
(not present versus present)
37/132 48/169 1.88 (1.01–3.47) 0.04 2.34 (1.2–4.58) 0.01
B
Factor definitions No. of patients
in each
group
No. of events/
No. of
patients
Breast cancer-specific survival
Univariable analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Tumor size
(T1/2 vs. T3/4)
138/33 24/171 3.5 (1.5–8.3) 0.004 3.42 (1.21–9.66) 0.02
Node status
(Yes vs. No)
90/69 22/159 4.6 (1.4–15.8) 0.01 4.05 (1.14–14.38) 0.03
Ki67 level, per 2.7 fold increase 25/174 1.4 (1.1–1.7) 0.009 1.05 (1.0–1.11) 0.06
ER Allred
(0.2 vs. 3–8)
16/157 25/173 4.3 (1.6–11.7) 0.005 7.98 (2.58–24.7) 0.0003
Aromatase status
(not present versus present)
37/132 24/169 2.82 (1.2–6.63) 0.02 3.76 (1.42–9.98) 0.008
a The four elements of the preoperative endocrine relapse index (PEPI) score (pathological T and N stage, surgical specimen ER and Ki67 status
has been previously described [14]
b Surgical specimen Ki67 was analyzed as the natural log interval, or per 2.7 fold increase according to the original scale of percentage values
[14]
c The ER analysis refers to the post-treatment values, before treatment all the tumors in this data set were ER positive. In the PEPI model, an
Allred cut off of 0 or 2 is used to define ER negative
d The aromatase expression status was defined as present or positive if any positive staining presented in invasive breast cancer cells. Table 4A
and B shows the RFS data and BCSS data, respectively
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prediction of neoadjuvant response to endocrine therapy,
but may help identify ER positive tumors with favorable
long-term outcomes.
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Fig. 2 Kaplan–Meier curves for relapse-free and breast cancer-
specific survival by aromatase protein expression status in cancer
cells. (a) Relapse-free survival (RFS) for patients with aromatase
protein expression positive (green or upper curve) versus negative
(red or lower curve) in cancer cells; (b) Breast cancer-specific
survival (BCSS) for patients with aromatase protein expression
positive (green or upper curve) versus negative (red or lower curve) in
cancer cells; Censorship observations are marked with open circles;
log rank tests were used to estimate the difference between Kaplan–
Meier curves for RFS and BCSS. 95% confidence intervals are
provided on each curve
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